Skip to content
← Back to this collection

PUBLICATIONS · 18757777

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2008 Nov 15
First author
Kobe C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Kobe C
      type
      Author
    2. name
      Dietlein M
      type
      Author
    3. name
      Franklin J
      type
      Author
    4. name
      Markova J
      type
      Author
    5. name
      Lohri A
      type
      Author
    6. name
      Amthauer H
      type
      Author
    7. name
      Klutmann S
      type
      Author
    8. name
      Knapp WH
      type
      Author
    9. name
      Zijlstra JM
      type
      Author
    10. name
      Bockisch A
      type
      Author
    11. name
      Weckesser M
      type
      Author
    12. name
      Lorenz R
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Kobe C
      type
      Author
    2. name
      Dietlein M
      type
      Author
    3. name
      Franklin J
      type
      Author
    4. name
      Markova J
      type
      Author
    5. name
      Lohri A
      type
      Author
    6. name
      Amthauer H
      type
      Author
    7. name
      Klutmann S
      type
      Author
    8. name
      Knapp WH
      type
      Author
    9. name
      Zijlstra JM
      type
      Author
    10. name
      Bockisch A
      type
      Author
    11. name
      Weckesser M
      type
      Author
    12. name
      Lorenz R
      type
      Author
    bibliography ids
    1. nci-bib-531a5eaa74c501c6a59d0070
    book metadata
    content sha256
    09af704de97e956a1272a8a983eae76ec8850116e1bb0ba85c360f38d0dd63ce
    document type
    citation
    dois
    1. 10.1182/blood-2008-06-155820
    electronic publication date
    display
    2008 Aug 29
    precision
    day
    year
    2008
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:18757777
    immutable id
    pubmed:18757777@09af704de97e956a1272a8a983eae76ec8850116e1bb0ba85c360f38d0dd63ce
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    10
    name
    Blood
    nlm unique id
    7603509
    pages
    3989-94
    volume
    112
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      18757777
      provenance
      batch id
      6281e3e555c9a831cffc
      provider
      NCBI PubMed ESummary
      record sha256
      f46915dedb89145289349e94645469b230fd852186475a8b4616d6c81e37ec12
      response sha256
      0bb4ba3914464c472d4206a84abe8224c9e76dc003114204593648964c5bf66c
      retrieved at
      2026-09-09T23:46:21.772457+00:00
      publication date
      display
      2008 Nov 15
      precision
      day
      year
      2008
      publication types
      1. Journal Article
      2. Multicenter Study
      3. Randomized Controlled Trial
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/18757777/
      title
      Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.

      Preserved source evidence · Not medical advice